Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to 14 new employees. The awards consist of options to purchase up to 228,400 shares of common stock under the Company's 2023 Inducement Plan.
The stock options feature a four-year vesting schedule, with 25% vesting after one year and the remaining shares vesting monthly at a rate of 1/48th over the subsequent 36 months, contingent on continued employment with Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), un'azienda biofarmaceutica in fase commerciale specializzata in terapie oncologiche, ha assegnato premi di incentivo a 14 nuovi dipendenti. I premi consistono in opzioni per acquistare fino a 228.400 azioni ordinarie nell'ambito del Piano di Incentivazione 2023 della Societ脿.
Le opzioni azionarie prevedono un piano di maturazione quadriennale, con il 25% che matura dopo un anno e le azioni rimanenti che maturano mensilmente a un ritmo di 1/48 nei successivi 36 mesi, subordinatamente alla permanenza in servizio presso Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), una empresa biofarmac茅utica en etapa comercial enfocada en terapias contra el c谩ncer, ha otorgado premios de incentivo a 14 nuevos empleados. Los premios consisten en opciones para comprar hasta 228,400 acciones ordinarias bajo el Plan de Incentivos 2023 de la Compa帽铆a.
Las opciones sobre acciones tienen un calendario de adquisici贸n de derechos de cuatro a帽os, con el 25% que se adquiere despu茅s de un a帽o y las acciones restantes que se adquieren mensualmente a raz贸n de 1/48 durante los siguientes 36 meses, condicionado a la continuidad del empleo en Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX)電� 鞎� 旃橂鞐� 欷戩爯鞚� 霊� 靸侅梾 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 14氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞙犾澑 氤挫儊鞚� 攵�鞐枅鞀惦媹雼�. 鞚� 氤挫儊鞚� 須岇偓鞚� 2023雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 斓滊寑 228,400欤�鞚� 氤错喌欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴鞙茧 甑劚霅╇媹雼�.
欤检嫕 鞓奠厴鞚� 4雲勱皠鞚� 氩犾姢韺� 鞚检爼鞚� 鞛堨溂氅�, 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆� 欤检嫕鞚� 鞚错泟 36臧涤洈 霃欖晥 毵れ洈 1/48鞌� 氩犾姢韺呺悩氅�, Syndax鞐愳劀 瓿勳啀 攴茧頃橂姅 瓴届毎鞐� 頃滍暕雼堧嫟.
Syndax Pharmaceuticals (NASDAQ : SNDX), une soci茅t茅 biopharmaceutique en phase commerciale sp茅cialis茅e dans les th茅rapies contre le cancer, a accord茅 des primes d'incitation 脿 14 nouveaux employ茅s. Ces primes consistent en des options d'achat pouvant aller jusqu'脿 228 400 actions ordinaires dans le cadre du Plan d'Incitation 2023 de la Soci茅t茅.
Les options d'achat d'actions suivent un calendrier d'acquisition sur quatre ans, avec 25 % acquis apr猫s un an et les actions restantes acquises mensuellement 脿 raison de 1/48 sur les 36 mois suivants, sous r茅serve de la poursuite de l'emploi chez Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit Fokus auf Krebstherapien, hat Anreizpr盲mien an 14 neue Mitarbeiter vergeben. Die Pr盲mien bestehen aus Optionen zum Kauf von bis zu 228.400 Aktien des Stammkapitals im Rahmen des Inducement-Plans 2023 des Unternehmens.
Die Aktienoptionen haben einen vierj盲hrigen Vesting-Zeitplan, wobei 25 % nach einem Jahr vesten und die restlichen Aktien monatlich mit einer Rate von 1/48 眉ber die folgenden 36 Monate vesten, vorausgesetzt, die Besch盲ftigung bei Syndax wird fortgesetzt.
- None.
- None.
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq:聽), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025聽the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj庐聽(revumenib), an FDA-approved menin inhibitor, and Niktimvo鈩� (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit聽聽or follow the Company on聽 补苍诲听.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.聽
Tel 781.684.9827
FAQ
What type of inducement awards did Syndax Pharmaceuticals (SNDX) grant in July 2025?
How many employees received Syndax (SNDX) inducement awards in July 2025?
What is the vesting schedule for Syndax's (SNDX) July 2025 inducement awards?
What is the purpose of Syndax Pharmaceuticals' (SNDX) inducement awards?
